39 active shortage notices across 8 countries · 5 anticipated.
Last updated 1 Nov 2026 · sourced from official medicines regulators
| high |
| 1 |
| 25 Sept 2026 |
| — |
| TGA |
| Netherlands | medium | 13 | 26 May 2026 | — | CBG-MEB |
| India | medium | 3 | 1 May 2026 | — | CDSCO |
| Belgium | medium | 1 | 7 Sept 2026 | 14 Oct 2026 | FAMHP |
| Peru | medium | 1 | 1 Mar 2020 | 1 Dec 2020 | DIGEMID |
| Malaysia | medium | 1 | 1 Jan 2020 | — | NPRA |
Yes. As of the latest regulator updates, Ondansetron has 39 active shortage notices across 8 countries (Canada, Colombia, Australia, Netherlands, India, Belgium and more). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Ondansetron shortages to product discontinuation, manufacturing problems, unexpected increases in demand. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 1 Dec 2020 to 11 Dec 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.